Several dedicated studies have investigated the pharmacodynamics and pharmacokinetics of potent oral P2Y12-ADP receptor antagonists in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) (Table 1). This evidence concerns the gene P2RY12 and chronic kidney disease.